Elebsiran clinical trials
Also written VIR-2218.
How each study uses elebsiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
12 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
Vir Biotechnology, Inc. (8) · Brii Biosciences Limited (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Virion Therapeutics (1)
Often tested with
Tested in the same studies.
Tobevibart (6) · VRON-0200 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test elebsiran, phase 3 first.
- Dec 2026A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtidePhase 3 · Vir Biotechnology, Inc.
- Nov 2026A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionPhase 2 · Vir Biotechnology, Inc.
Studies
Open first, then newest update. How each study uses elebsiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionActive, not recruitingPhase 3Vir Biotechnology, Inc.NCT06903338Written as Elebsiran
- A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218CompletedPhase 1Vir Biotechnology, Inc.NCT05844228Written as VIR-2218
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis BActive, not recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT06092333Written as VIR-2218 and peginterferon alfa-2a
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434CompletedPhase 1Vir Biotechnology, Inc.NCT05484206Written as VIR-2218
- Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide TherapyCompletedPhase 1Virion TherapeuticsNCT06070051Written as VIR-2218
- Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) InfectionCompletedPhase 2Brii Biosciences LimitedNCT04749368Written as BRII-835 (VIR-2218)
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideActive, not recruitingPhase 3Vir Biotechnology, Inc.NCT07128550Written as Elebsiran
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.Active, not recruitingPhase 2Vir Biotechnology, Inc.NCT05461170Written as VIR-2218
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionCompletedPhase 2Vir Biotechnology, Inc.NCT04412863Written as VIR-2218
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionActive, not recruitingPhase 2Vir Biotechnology, Inc.NCT07142811Written as Elebsiran
- Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland ChinaCompletedPhase 2Brii Biosciences LimitedNCT04507269Written as VIR-2218
- Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis BCompletedPhase 1/2Vir Biotechnology, Inc.NCT03672188Written as VIR-2218
Given beside what is tested · 5 — elebsiran is usual care or a partner of the new treatment
- A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)RecruitingPhase 2Brii Biosciences LimitedNCT06650852Written as BRII-835 (VIR-2218)
- Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)CompletedPhase 2Brii Biosciences LimitedNCT06491563Written as BRII-835 (VIR-2218)
- Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionCompletedPhase 2Vir Biotechnology, Inc.NCT04856085Written as VIR-2218
- A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B InfectionCompletedPhase 1/2Vir Biotechnology, Inc.NCT05612581Written as VIR-2218
- Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)CompletedPhase 2Gilead SciencesNCT04891770Written as VIR-2218
Codes
What other systems call elebsiran · ClinicalTrials.gg INT018332
- UNII (FDA) W982Y6N4X7ELEBSIRANOne source FDA
- NCI Thesaurus C190492ElebsiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W982Y6N4X7 | ELEBSIRAN | One source FDA |
| NCI Thesaurus | C190492 | Elebsiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.